This respiratory illness season, wearing a mask is required in patient and resident areas at Sunnybrook. Read our visitor guidelines »

Cancer trials
Hospital  >  Care Programs  >  Odette Cancer Program  >  Clinical trials

Trial details

A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma

To find out more about this trial and your cancer treatment options, please speak with your doctor.

Trial short name: GA.4

Official title: A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma

Principal Investigator: Dr. Michael Raphael

Cancer type: Gastrointestinal
Cancer location: Esophagus
Disease stage: Early Cancer
Trial phase: Phase 2
Intervention: Drug: Paclitaxel, Drug: Ramucirumab, Drug: Zanidatamab

Registration #: NCT06043427

Contact e-mail: cancerclinicaltrials@sunnybrook.ca

Trial description:
The purpose of this study is to compare the usual approach alone to using zanidatamab plus the usual approach. The addition of zanidatamab to the usual approach could shrink cancer. But, it could also cause side effects. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if adding zanidatamab to the usual approach reduces the risk of cancer getting worse by at least 37% compared to the usual approach.